Foley  

Sica  

Pathogenesis and Management of Cardiovascular Disease (CVD) in Chronic Kidney Disease
Robert N. Foley, MD, and Domenic A. Sica, MD. (ASN Renal Week, 2006). Foley: How are classic and novel risk factors related to outcome in CKD patients as well as in dialysis patients? What can we learn from Framingham data? From NHANES? Which of the classical risk factors works in the opposite direction when GFR is low? To what extent have patients with mild-moderate CKD been excluded from the major cardiovascular trials? What can we learn from analysis of these subsets? How do the observational data differ from randomized, controlled trials?
Sica: How are the pathogenses of CKD and CVD (cardiovascular disease) related? Where do both impact the RAS (renin-angiotensin system)? How does ACE inhibition affect different parts of the cardiovascular system? What conclusions can we draw from AASK? How can we rationally choose drugs from different classes to treat hypertension? How should different calcium-blockers and ACE inhibitors be used in CKD? How do ACE inhibitors and ARBs compare? (ASN Renal Week Official Symposium, 2006).
(more...)



Townsend  

Secondary Hypertension, including Chronic Kidney Disease
Ray Townsend, MD. (ASN Board Review Course, 2006). Townsend: Renin system activation, mineralocorticoid excess states, pheo, aortic coarctation, and primary renal disease are the main types. What is the best means to diagnose renovascular HTN? What are less common types of RV HTN? How do we approach low renin, high aldo HTN? What are diagnostic criteria (aldo/renin ratios, urinary aldos, etc.), and what are the treatment options besides surgery? How do we approach Cushing's, pheo, and hyper- and hypothyroidism and HTN? What are the main genetic disorders? Liddle, GRH, activating MR receptor mutations, and 11-beta-hydroxysteroid dehydrogenase? What is Gordon's syndrome? What are the main drug-induced causes, including anti-angiogenesis agents? What's new in treating HTN associated with CKD?
(more...)



White  

Calhoun  

Cosio  

Resistant Hypertension: Reducing Cardiovascular Events
(ASN Renal Week Official Symposium. November, 2005, Philadelphia, PA)
White: During introductory remarks, two cases of resistant hypertension are presented to set the stage. A young woman who works in a hospital on 3 drugs with BP 160/100, and an elderly retiree who finds that his AM BP is quite elevated on home monitoring. Calhoun: What is the prevalence of primarly aldosteronism in hypertensives, and how does this depend on the resistance of hypertension to treatment? What percent of hypertension is low-renin. To what degree does resistant hypertension respond to aldosterone blockers, and does this depend on aldosterone excretion rates? How are high-aldosterone hypertensives different from those with normal aldo levels in terms of endothelial dilation, LVH, and other measures? How can aldosterone blockade as well as salt intake modify endothelial vasodilatory capacity and LVH? White: In resistant hypertension, what other drugs can we use? How do CCB/ACE combos compare to BB/D? What dose of diuretic should be added to an ACE/ARB regimen? Is ARB half-life important? What are new drugs on the horizon? Cosio: What should target LDL-C (LDL cholesterol) levels be for CKD patients? How do CV risk factors cluster in CKD patients? Which dyslipidemias are associated with increased risk? How can one treat low HDL-cholesterol? What did the ALERT and 4-D trials show? How do we explain the negative results of the 4-D trial?
(more...)
Updated: May 09, 2008 (M09)
M09 Darapladib lowers the activity of inflammatory enzyme associated with vascular plaque.
M07 S100A1 protein found in heart, blood vessels; linked to heart damage and to hypertension.
M07 Women at high risk for CV events are not benefitted by homocysteine-lowering regimen of B vitamins (JAMA).
M05 ASN Renal Week abstract archives 2003-2006 now available on-line in .pdf format.
M04 Nature genetics: More obesity genes found
M02 New ACE 2 activator compounds lower blood pressure in rats and also reduce cardiac and renal fibrosis.
M01 Obesity linked to heart failure and inflammatory mediator elevation in observational study.
A30 Scientists synthesize molecule capable of releasing hydrogen sulfide over extended periods - possible role in donor organ preservation?
A29 High blood theobromine levels (presumably from eating chocolate) may protect against pre-eclampsia.
A28 Hypertension seen in the emergency department frequently misattributed to trauma, stress, and not followed up.
A25 First ever activator of ENAC sodium channel developed.
A23 High adiponectin levels linked to kidney dysfunction and albuminuria.
A22 FDA approves compact heart assist device from Thoratec.
A21 International study of chemicals in urine links blood pressure to diet and gut bacteria.
A21 Chocolate lowers LDL cholesterol by 5% in RCT.
Industry Advances Emphasis
archive
Secondary Hypertension, including Chronic Kidney Disease ASN Board Review 2006
Pathogenesis and Management of Cardiovascular Disease (CVD) in Chronic Kidney Disease ASN Renal Week 2006
Update on Vascular Calcification in Chronic Kidney Disease (CKD) Patients (Isaac Teitelbaum, MD; Robert Toto, MD; Dennis Andress, MD; Gerard M. London, MD) ADC 2006 (audio only)
Emerging New Agents in Diabetic Kidney Disease (Lewis) ASN 2005 Renal Week
Coronary Angioplasty and Stenting: Indications and Results (Williams) ASN 2005 Renal Week
Webcasts from the ISH 2006 meeting in Fukuoka, Japan, October, 2006 (ISH 2006) ADC 2006 (audiofiles)
Blood Pressure on Dialysis (Kalantar-Zadeh, Reams, Misra, Sherman, Charra) ADC 2006 (audiofiles)
Uric acid as a Uremic Toxin (Ikizler, Nakagawa) RRI 2006, Part 2 (handouts)
Sodium as a Uremic Toxin (Ritz) RRI 2006, Part 2 (handouts)
Kidneys, Hearts, Hormones, Immunomodulators and More: Complex Systems Requiring Integrated Understandings (Adeera Levin) RRI 2006, Part 2 (handouts)
Cardiovascular Disease Causes and Consequences of Sympathetic Hyperactivity in CKD (Kotanko) RRI 2006, Part 3 (handouts)
Dry Weight Assessment and Rebound (Kuhlmann, Greenwood) RRI 2006, Part 3 (handouts)
Resistant Hypertension: Reducing Cardiovascular Events (White, Calhoun, Cosio) ASN Renal Week 2005
Hypertensive Urgencies and Emergencies: Clinical Syndromes And Therapy (Textor) ASN Renal Week 2005
Pathogenic Mechanisms of Ischemic Nephropathy (Lerman, Navar, Wilcox, Julliard) ASN Renal Week 2005 (audiofiles)
Inflammation, Dyslipidemia and the Kidney (Massy, Tonelli, Danovitch, Kasiske, Landray) ASN Renal Week 2005 (audiofiles)
Refractory Hypertension: Pathogenesis, Diagnosis and Therapy (Townsend, Norris, Sica) ASN Renal Week 2005 (audiofiles)
Childhood Hypertension: The View in 2005 (Flynn, Bertram, Portman) ASN Renal Week 2005 (audiofiles)
Genetic Hypertension and the Cortical Collecting Duct (CCD): What Every Nephrologist Must Know! (Ferrari, Luft, Geller, Auchus) ASN Renal Week 2005 (audiofiles)
Kidney-Heart Interactions (Pfeffer, Ritz, Burnett) ASN Renal Week 2005 (audiofiles)
Aldosterone, Resistant Hypertension and Target Organ Injury (Calhoun, Goodfriend, Weber, Geller) ASN Renal Week 2005 (audiofiles)
Cardiovascular Risk Factors and Renal Disease (Vaziri, Bostom, Hsueh) ASN Renal Week 2005 (audiofiles)
Emerging Concepts in Cardiovascular Disease (Stenvinkel, Moe) ASN Renal Week 2005 (audiofiles)
Treatment of Hypertension in CKD (Adler, Toto, Levin, Peixoto, Weir) ASN Renal Week 2005 (audiofiles)
Influence of Lifestyle on Hypertension, CKD, and CVD (Kramer, Tuttle) ASN Renal Week 2005 (audiofiles)
Secondary Hypertension (Gomez-Sanchez, Dworkin, Toto) ASN Renal Week 2005 (audiofiles)
The Heart on Dialysis (Part 1) (Kalantar-Zadeh, Aggarwal, Kopple, Saran) ADC 2005 (audiofiles)
Hypertension, CKD, and CVD Risks (Moe, London, Sarnak) ADC 2005 (audiofiles)
Hypertension in Special Populations (Portman, Izzo, Norris, August, Sarnak) ADC 2005 (audiofiles)
The Heart on Dialysis (Part 2) (Beddhu, Amerling, Sherman, Misra, Herzog) ADC 2005 (audiofiles)
Controlling Volume Status and Blood Pressure in PD Patients (Faber, Selgas, Rippe) ADC 2005 (audiofiles)
The Unexplained Relationship of Blood Pressure to Survival in the Dialysis Patient: A New Explanation (Saran) RRI 2005 (audiofiles)
The Impact of Post-Dialysis Weight on Patient Outcomes in Hemodialysis (Charra) RRI 2005 (audiofiles)
Renin-Angiotensin System Actions and Interactions in CKD (Anderson) ASN 2004
New Insights in the Pathogenesis of Uric Acid Nephrolithiasis (Sakhaee) ASN 2004
When and How to Use the Selective Aldosterone Receptor Antagonists to Optimize Cardiorenal Event Reduction (Bakris) ASN 2004
Secondary Hypertension Including Chronic Kidney Disease (Toto) ASN Board Review 2004
Uric acid, the kidney, and the pathogenesis of hypertension. Two parts. (Johnson) ASN Renal Week
Therapy in ischemic nephropathy : A data based approach (Textor) ASN Renal Week
Role of the sympathetic nervous system in the control of hypertension (Campese) ASN 2002 Renal Week
Renal autoregulation and hypertension injury: Do all agents that lower blood pressure protect the kidney? (Griffin) ASN 2002 Renal Week
Ideal actions of anti-hypertensive drugs (Ruilope) ASN 2002 Renal Week
The Malnutrition - Inflammation - Atherosclerosis or MIA syndrome (Stenvinkel) ASN 2002 Renal Week
Microalbuminuria: The kidney's message about the systemic vasculature (Tuttle) ASN 2002 Renal Week
Treatment of hypertension in renal parenchymal disease (Bakris) ASN 2002 Board Review Course
How to reduce CV risk in the patient with chronic kidney disease (Culleton) NKF 2002 Spring Meeting
How do calcium/phosphorus abnormalities contribute to CV risk? (Goodman) NKF 2002 Spring Meeting
Current concepts in the diagnosis and management of pediatric hypertension (Portman) NKF 2002 Spring Meeting
Aldosterone, salt and cardiac fibrosis (Funder)

The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) Double-Blind Crossover Trial in Patients With Low-Renin Hypertension and Elevated Aldosterone-Renin Ratio (Hood SJ et al) Circulation (Jul 07)
A different approach to resistant hypertension (Hirsch S) Cleveland Clinic J Med (Jun 07)
Intensive versus moderate blood-pressure control in normotensive patients with type 2 diabetes (Briggs J) NCPN Jun 07
Lipoprotein metabolism and lipid management in chronic kidney disease JASN 04-07
Controveries in renal artery stenosis: A review by the American Society of Nephrology Advisory Group on Hypertension (Levin et al) Am J Nephrol 04-07
ACCF/AHA 2007 Clinical Expert Consensus Document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain. Circulation (02-07)
Physical Activity Intervention Studies: What We Know and What We Need to Know (AHA) Circulation 12-06
Aldosterone and Cardiovascular Disease. Smoke and Fire (Calhoun). Circulation 12-06
Effectiveness of Management Strategies for Renal Artery Stenosis: A Systematic Review (Balk et al) Annals Intern Med 12-06
Angiotensin-converting enzyme-2 (ACE-2) - a new player in the genesis of glomerular injury? (Comment by Ritz on paper by Oudit et al) JASN 10-06
Obesity: Growing Impact on CKD (McGill, Furth, Kaskel) Adv Chronic Kidney Dis 10-06
Management of dyslipidemias in patients with diabetes and chronic kidney disease (Molitch). CJASN 09-06
HYPERTENSION GUIDELINES
K-DOQI Lipid Guidelines
JNC 7
HTN in Pregnancy
ADA Clinical Practice Recs
Canadian Lifestyle Guidelines
Salt Reduction Guide
DASH Diet Facts
Guidelines.gov
Renovascular HTN (Nuc Med)
HDCN Topic Pages (KEY)
Ambulatory BP Monitoring
Arm Cuff Measurement
ACEI, AII Blockers
Beta Blockers
Ca Antagonists
Beta Blockers
Heart in HTN
Kidney in HTN
Genetics
Hormonal Physiology
Inflammatory Syndrome
Salt Sensitivity
Outcomes
Elderly
Endocrine
Syndrome X, Diabetes
Lipid Disorders
Smoking
Renovascular
HTN in Women
PATIENT LINKS, TRIALS
American Heart Assoc
National Stroke Assoc
NHLBI
Clinical Trials (NIH)
CV Risk Calculator

Dr. Carmine Zoccali, M.D.
Postgraduate Professor of Nephrology, Director, Center for Clinical Physiology, Renal Diseases and Hypertension of the Italian Research Council, Reggio Calabria, Italy (European Editor)